ACHC vs PTRN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ACHC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACHC and PTRN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACHC and PTRN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue.

Full ACHC guide

Pattern Group Inc. helps consumer brands sell on global ecommerce marketplaces, and it does so mostly by taking title to the goods. Brands sell products to Pattern at agreed prices, Pattern lists and sells them to consumers on more than 70 marketplaces including Amazon, Walmart.com, Target.com, TikTok Shop, eBay, Tmall, JD and Mercado Libre, and Pattern keeps the spread after marketplace commissions, advertising and fulfillment. The company works with more than 250 brands across health and wellness, beauty and personal care, home, pet, sports and consumer electronics, sells into more than 100 countries, and says it has accumulated over 91 trillion ecommerce data points feeding the machine learning models that set prices, bids and inventory forecasts. Around 510 engineers and data scientists support the platform, which the company markets as Pattern Intelligence (or Pi) following a May 2026 launch, and it holds 44 patents issued or pending. Pattern listed on Nasdaq on September 19, 2025 at $14.00 per share and reports in U.S. dollars.

Full PTRN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACHC drivers: Structural demand for behavioral health; Bed expansion and de novo growth.
• PTRN drivers: Growth from brands already on the platform; Diversification away from Amazon and the United States.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Legal and regulatory exposure is the defining risk. For PTRN, the concentration risk is stated plainly in Pattern's own filings: 93% of 2025 revenue came from consumer product sales on Amazon, the relationship runs on non-negotiable click-through terms that either side can end at will, and the company discloses that it has previously experienced account suspensions, payment-term changes and higher fulfillment fees.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACHC if you believe its drivers more; PTRN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACHC and PTRN guides.

ACHC. Acadia trades around $30 per share after a volatile year that saw the stock swing from roughly $11 to $33, reflecting litigation and guidance concerns. On a low-single-digit forward EBITDA multiple and mid-teens forward P/E against its guidance, the market is pricing meaningful legal and reimbursement uncertainty. Reported earnings remain depressed by legal and interest costs even as adjusted metrics grow.

PTRN. All figures are in U.S. dollars. Pattern screens cheap on sales at roughly 1.3x because most of its revenue is resold merchandise rather than software, so the sales multiple is not comparable to marketplace-software peers; the adjusted EBITDA multiple near 16x on 2026 guidance is the more useful anchor. Trailing GAAP net income of roughly $26 million, and the very high P/E that follows, reflects the one-time IPO stock compensation charge taken in the third quarter of 2025 rather than the current earnings run rate, which annualises closer to $113 million based on first-half 2026 results.

Headline figures (approximate, July 2026): ACHC shows revenue (2025) ~$3.31B, 2026 revenue guidance ~$3.37B to $3.45B, 2026 adj. ebitda guidance ~$580M to $615M, 2026 adj. eps guidance ~$1.35 to $1.60; PTRN shows revenue (ttm through q2 2026) ~$3.01B, up ~45% year over year in H1, q2 2026 revenue ~$877M (+47% YoY), net income ~$27M, diluted EPS ~$0.15, fy2026 guidance Revenue ~$3.42B to ~$3.46B (+37% to +38%); adjusted EBITDA ~$211M to ~$213M, market cap ~$3.8B (~177M Series A and Series B shares near ~$21).

ACHC and PTRN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACHC and PTRN exposure against your real portfolio. It is not an investment adviser.